Covishield accounted for nearly 80 per cent of Covid-19 vaccine doses administered in India. AstraZeneca said its decision to withdraw marketing authorisation of Vaxzevria was due to a “surplus of available updated vaccines” since the pandemic.
News
Stopped producing Covishield in Dec 2021: SII after AstraZeneca recall
May 14, 2024Covishield accounted for nearly 80 per cent of Covid-19 vaccine doses administered in India. AstraZeneca said its decision to withdraw marketing authorisation of Vaxzevria was due to a “surplus of available updated vaccines” since the pandemic.